Oramed Pharmaceuticals
ORMP
21 hedge funds and large institutions have $910K invested in Oramed Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
7% more capital invested
Capital invested by funds: $850K → $910K (+$60K)
0.07% more ownership
Funds ownership: 1.05% → 1.12% (+0.07%)
13% less funds holding
Funds holding: 24 → 21 (-3)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
91% less call options, than puts
Call options by funds: $3K | Put options by funds: $32K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$187K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$38K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
+$18.7K |
| 4 |
PCM
Penserra Capital Management
Orinda,
California
|
+$10.9K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$85K |
| 2 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$31.4K |
| 3 |
FNBT
FineMark National Bank & Trust
Fort Myers,
Florida
|
-$21K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$18.7K |
| 5 |
Morgan Stanley
New York
|
-$17.6K |
ORMP Hedge Fund Activity: Q1 2017 in Review
21 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2017, worth a combined $910K — up 7.1% from $850K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ORMP and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Glenmede Trust, opening a new position worth an estimated $187K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $85K sold.
- 21 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2017, down from 24 in Q4 2016.
- Funds reported $910K of Oramed Pharmaceuticals stock for Q1 2017, up 7.1% quarter-over-quarter.
- 1 fund opened new Oramed Pharmaceuticals positions in Q1 2017 and 4 closed out, a net change of -3 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2017 was Glenmede Trust, an estimated $187K added.
- The largest Oramed Pharmaceuticals seller in Q1 2017 was Virtu KCG Holdings, an estimated $85K sold.
Based on aggregated 13F filings for Q1 2017.